A phase III, multicentre, randomized, open-label study of atezolizumab (anti-PD-L1 antibody) plus bevacizumab plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablationR SURGICAL RESECTION OR ABLATION

  • Poursoltan, Pirooz (Primary Chief Investigator)
  • Chapman, Nicola, (Clinical Trial Unit Staff)
  • Parshionikar, Abhijit, (Clinical Trial Unit Staff)

Project: Other

Project Details

AcronymIMbrave050
StatusActive
Effective start/end date11/12/1930/09/24